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Down-regulation of tissue lipoprotein lipase expression in
experimental chronic renal failure
NOSRATOLA D. VAZIRI and KAIHuI LIANG
Division of Nephrology, Department of Medicine, University of California at Inine, I,'vine, California, USA
Down-regulation of tissue lipoprotein lipase expression in experimental
chronic renal failure. Chronic renal failure (CRF) is associated with
hypertriglyceridemia, impaired clearance of vcry low density lipoproteins(VLDL) and chylomicrons and their remnants as well as triglyceride-
enrichment of various lipoproteins. These abnormalities are indicative of
depressed lipoprotein lipase (LPL)-mediated hydrolysis of triglycerides in
VLD and chylomicrons. In fact, impaired post-heparin lipolytic activity
and decreased adipose tissue LPL activity have been previously demon-
strated in CRF. The reduction in LPL activity in CRF has been attributed
to PTH-induced insulin resistance and the presence of excess lipasc
inhibitors in uremic plasma. However, the effect of CRF on gene
expression of LPL has not been elucidated and was studied here.
Heparin-releasable, detergent-extractable and total LPL activities, as well
as LPL mRNA of the heart, soleus muscle and fat body were determined
in male Sprague-Dawlcy rats at baseline and on weeks 1, 3 and 6 following
5/6 nephrectomy (CRF group) or sham operation (control group). The
CRF group exhibited a marked and steady rise in plasma triglycerides
along with a steady decline in LPL activities and mRNA levels of all tissues
studied. In contrast, the study parameters remained virtually unchanged
throughout the study period in the control group. A strong inverse
correlation was found between plasma triglycerides and LPL activity in the
study animals. LPL activity was directly related to LPL mRNA. We
conclude that CRF results in marked down-regulation of LPL expression
that can contribute to dyslipidemia and altered energy metabolism in
uremia. The effect of depressed LPL expression is compounded by the
previously demonstrated elevations in uremic plasma of Apo C-Ill and
pre--HDL, which are potent inhibitors of LPL.
Chronic renal failure (CRF) is associated with marked plasma
lipoprotein abnormalities representing a highly atherogenic pro-
file [1—3]. These abnormalities include hypertriglyceridemia, ele-
vated very low density lipoprotein (VLDL), Apo B and Apo C-Ill
and depressed HDL, and Apo A-I concentrations and reduced
Apo C-I! to Apo C-ITT ratio [1, 2, 4, 5]. Tn addition, the
composition of various plasma lipoproteins is abnormal, further
contributing to the atherogenic diathesis in CRF. For instance,
triglyceride contents of VLDL, intermediate density (IDL), low-
density (LDL) and high density lipoproteins are increased in
CRF. Furthermore, apoprotein B-48, which is normally absent, is
present in VLDL, the apoprotein A-IV content of VLDL, IDL
and LDL is abnormally high, and Apo C and Apo E, which are
normally absent, are present in LDL particles in CRF [6].
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Lipoprotein lipase (LPL) is the rate-limiting step in catabolism
of triglyceride-laden lipoproteins. LPL deficiency can lead to
reduced clearance, accumulation and altered composition of these
lipoproteins and their remnants in the circulation, features that
are prominently evident in CRF [7, 81. In fact, Goldberg et aJ have
demonstrated a marked reduction of lipolytic activity of the
adipose tissue in patients with end-stage renal disease [8, 9]. The
reduction of LPL activity in CRF has been attributed to PTH-
mediated insulin resistance [3, 10] and elevated concentration of
lipase inhibitor(s) in the uremic plasma [11—14]. However, Joven
et al have shown a parallel reduction in plasma immunodetectable
LPL in a group of patients with end-stage renal disease main-
tained on hemodialysis therapy [151. This observation suggests
that cellular production and/or release of LPL may be defective in
CRF. The present study was designed to test the hypothesis that
LPL deficiency in CRF is at least, in part, related to depressed
tissue LPL expression. To this end, gene expression of LPL was
studied in relevant tissues in the course of CRF in rats.
Methods
Animal model
Male Sprague-Dawley rats (Charles River Inc., Wilmington,
MA, USA) weighing 280 to 300 g were used. The animals were fed
Purina Rat Chow (Purina Mills, Brentwood, MO, USA) and water
ad libitum. They were housed in a temperature and light regulated
space with 12-hour light (500 lux) and 12-hour dark (<5 lux)
cycles. The animals were randomized into CRF and the normal
control groups. Animals assigned to the CRF group were sub-
jected to 5/6 nephrectomy as follows. Under general anesthesia
(pentobarhital 50 mg/kg, i.p.), the animals underwent a 2/3 left
nephrectomy through a dorsal incision. This was followed by a
right nephrectomy four days later to produce CRF. Animals
assigned to the normal control group underwent sham operation.
Strict hemostasis and aseptic measures were observed during the
surgical procedure. Subgroups of animals were studied at weeks 1,
3 and 6 following nephreetomy or sham operation. On each
occasion, blood pressure was determined using a tail sphygmoma-
nometer (Harvard Apparatus, South Natick, MA, USA). A 24-
hour urine collection was obtained for measurement of creatinine
clearance prior to final experiment. The animals were then
anesthetized and killed by exsanguination and heart, soleus
muscle and epididymal fat body were removed immediately.
Serum concentrations of cholesterol, triglycerides and creatinine
were measured using standard laboratory techniques.
Earlier studies have revealed that regular administration of
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erythropoietin (EPO) mitigates hyperlipidemia in patients with
end-stage renal disease [16]. In an attempt to determine if the
effect of EPO therapy is mediated by altered LPL expression, a
group of EPO-treated CRF animals was included. These animals
were treated with intraperitoneal injections of recombinant EPO
(Epogen; Amgen Inc., Thousand Oaks, CA, USA) 150 units twice
weekly for six weeks. The EPO dosage employed here was based
on our earlier studies which demonstrated that the dose given was
sufficient to prevent anemia of CRF in this model [17].
RNA preparation and Northern blot analysis
The rats were killed between 9 and 11 a.m. The tissues were
removed immediately, frozen in liquid nitrogen and stored at
—70°C until processed. Total RNA was prepared from 1 g of
tissue with RNAzo1 using the manufacturer's recommended pro-
cedure (Tel-Test Inc., Friendswood, TX, USA) as previously
described [181. RNA concentration was determined from the
absorbance at 260 nm using a spectrophotometer (Gene-Quat;
Bio-Rad, Hercules, CA, USA). Twenty-five microgram aliquots of
total RNA were denatured in 2.2 M formaldehyde at 65°C for 15
minutes and run on 1.2% agrose/2.2 M formaldehyde gel at 70 V
for three hours. The separated RNA was transferred to the nylon
membrane (Zeta probe; Bio-Rad) by a capillary blotting method
in 6 X SSC buffer overnight and immobilized by UV irradiation
(Ultraviolet Crosslinker; Fisher Scientific, Pittsburgh, PA, USA).
The membrane was incubated at 65°C in a solution containing 5 X
SSPE, 5 X Denhard's, 1% SDS and 100 pg/mI salmon sperm
DNA for two hours. The eDNA probe for mouse LPL (1.5 Kb
EcoR I fragment of PG2mL5D) [19] and rat glyceraldehyde
phosphate dehydrogenase (GAPDH) (1.3 Kb PstI fragment) were
obtained from American Type Culture Collection (Rockville,
MD, USA) and labeled with [32P] dCTP (3000 Ci/mmol; New
England Nuclear Inc., Boston, MA, USA) by the random primer
method (Promega Inc., Madison, WI, USA). Hybridization was
carried out at 60°C in a prehybridization solution with 32P labeled
eDNA. The blots were washed twice in 2 >< SSPE/0.5% SDS
solution at room temperature, twice in 1 X SSPE/0.5% SDS
solution at 37°C, and twice in 0.1 X SSPE/0.5% SDS solution at
65°C, for 15 minutes each. The washed blots were exposed to
X-ray film (New England Nuclear Inc.) at —80°C for two to six
hours for GAPDH and two to three days for LPL. The autora-
diographs were scanned with a laser densitometer (Molecular
Dynamics, Sunnyvale, CA, USA) to determine relative mRNA
levels. The values obtained for constitutively expressed GAPDH
gene were used as an internal control.
LPL catalytic activity
The LPL enzymatic activity was determined in the fraction
released by heparin (HR) and the fraction remaining in tissue
after heparin extraction (EXT). In brief, samples of heart, soleus
muscle and fat body were minced, and 100 mg samples of the
minced tissue were incubated in Krebs-Ringer phosphate (KRP)
buffer containing 0.05 mg/mI heparin at 37°C for 30 minutes. At
the end of the incubation, a 0.2 ml aliquot of the bathing buffer
was removed and assayed for LPL activity as described below. The
tissues were then washed with PBS and homogenized in a buffer
containing sodium deoxycholate (2 mg/mi), nonidet P40 (0.08
mg/mi) (Boehringer Mannheim Corp., Indianapolis, IN, USA),
heparin (0.05 mg/mi), bovine serum albumin (10 mg/mi) and
Table 1. Serum concentrations of triglyderides, cholesterol and
creatinine, creatinine clearance, body weight, heart weight, systolic
blood pressure and hematocrit in the normal control (NL) rats and
those with chronic renal failure treated with placebo (CRF) and EPO
(CRF/EPO)
NL
(N = 6)
CRF
(N = 6)
CRF/EPO
(N = 6)
P
values"
Serum triglyceride
mg/dl 43.5 1.6 209.0 22.9 161.1 9.4 <0.0001
Serum cholesterol
mg/c/I 63.9 4.0 170.9 12.7 152.0 13.1 <0.0001
Serum creatinine
mg/dl 0.6 0.1 1.6 0.2 1.5 0.2 <0.0001
Creatinine clearance
mI/mm 1.5 0.20 0.5 0.05 0.7 0.10 <0.0001
Body weight g 436.8 3.3 405.5 5.9 403.3 2.5 <0.001
Heart weight g 1.47 0.04 1.46 0.02 1.78 0.04 <0.05
Blood pressure 103.3 3.1 135.0 2.7 180.0 2.9 <0.001
mm Hg
Hematocrit % 46.5 1.5 38.1 0.6 51.1 1.4 <0.001
Data represent values obtained at the end of the 6-week observation
period. Data are expressed as mean SEM.
a One-way ANOVA
sucrose (0.25 M). After eentrifugation, the aqueous layer was
recovered, and a 0.2 ml aliquot was obtained for LPL activity
assay. A [14C] trioiein-containing substrate (Amersham Life Sci-
ence Inc., Arlington Heights, IL, USA) was emulsified with
lecithin (Sigma) and mixed with human serum as a source of Apo
C-I! as described previously [20]. Two hundred microiiters of HR
and EXT samples were incubated with substrate at 37°C for 60
minutes. The ineubations were terminated and [14C1 free fatty
acids were extracted with a methanol-chioroform-heptane mix-
ture and assayed for radioactivity (Model LS 9000; Beckman Inc.,
Fullerton, CA, USA). Activity was expressed as nanomoies (nano
equivalents) of free fatty acid (FFA) released per minute per
gram of the tissues [21].
Statistical analyses
Anaiysis of variance (ANOVA), regression analysis and Stu-
dents' t-test were used in statistical evaluation of the data that are
expressed as mean SEM. P values equal to or less than 0.05 were
considered significant.
Results
General data
Data are summarized in Table 1. As expected, the CRF group
exhibited a significant increase in serum creatinine concentration
and a significant fali in creatinine clearance. In addition, the CRF
animals showed a significantiy higher arteriai blood pressure and
a significantly lower body wt when compared with the sham-
operated normal control group. Serum triglyceride concentration
was markedly elevated in the CRF group as compared to the
normal control animals.
LPL mRNA and enzymatic activity
Soleus muscle. Data are shown in Figures 1 and 2. Heparin-
releasable, detergent-extractable and total LPL activities of the
soleus muscle in the CRF group began to fall beyond week I
reaching statistical significance on weeks 3 and 6. This was
accompanied by a parallel fall in the soleus muscle LPL mRNA in
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Fig. 2. A representative autoradiograph of the Northern blot of heart, soleus
muscle and adipose tissue LPL and the corresponding GAPDH in the normal
control animals (NL, lane A) and those with chronic renal failure (CRF) at
week 1 (lane B), week 3 (lane C) and week 6 (lane D). Total RNA (25
/.Lg/lane) was isolated from tissues as described in the Methods section,
and separated by electrophoresis on 1.2% agarose/2.2 M formaldehyde gel.
RNA was transferred to a nylon filter and hybridized with the 32P-labeled
full-length eDNA to mouse LPL mRNA and 1.3 kb eDNA to rat GAPDH
mRNA used to control for possible variations in the loading dose.
Heart. Data are displayed in Figures 2 and 3. As with the soleus
muscle, heart tissue LPL activity and mRNA in the CRF group
declined steadily beyond week 1 yielding values that were signif-
icantly lower than the corresponding values found at baseline and
in the normal control group. In contrast, values obtained in the
control group remained virtually unchanged throughout the study
period. These observations suggest that the decline in LPL activity
and mRNA in the CRF group was not a function of time per se.
Adipose tissue. Data are illustrated in Figures 2 and 4. The
heparin-releasable, detergent-extractable and total LPL activities
of the adipose tissue began to decline beyond week 1 in the CRF
group, reaching values which were significantly less than those
obtained at baseline and in the normal control group. No signif-
icant change was observed in adipose tissue LPL activity in the
control group. Although the adipose tissue LPL mRNA fell in the
CRF group, the difference did not reach statistical significance.
Correlations
A significant inverse correlation was found between the total
LPL activity and serum triglyceride level in the entire study
animals (r =
—0.82, P < 0.01 for heart; r = —0.85, P < 0.01 for
muscle; and r =
—0.75, P < 0.02 for adipose tissue; Fig. 5). A
direct correlation was found between LPL mRNA and activity in
the study animals (r = 0.86, P < 0.05 for heart; r = 0.87, P < 0.01
for muscle; Fig. 6).
the CRF group. In contrast, soleus muscle LPL activity and
mRNA remained unchanged throughout the study period in the
sham-operated control group.
Effect of EPO therapy
EPO therapy led to correction of CRF anemia and a significant
rise in arterial blood pressure as compared to the placebo therapy.
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Fig. t. Longitudinal measurements of soleus muscle LPL activity and
,nRNA (normalized against corresponding GAPDH mRNA) in the normal
control (solid lines) and chronic renal failure (dotted lines) groups. LPL
activity was measured as heparin-releasable (1-IR) and detergent-extract-
able (EXT) fractions and total activity (HR + EXT) as described in the
Methods section. Data are given as mean SEM. N = 6. *P 0.02.
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Fig. 3. Longitudinal measurements of the heart muscle LPL activity and
mRNA (normalized against corresponding GAPDH mRNA) in the normal
control (solid lines) and chronic renal fitilure (dotted lines) groups. LPL
activity was measured as heparin-releasable (HR) and detergent-extract-
able (EXT) fractions and total activity (HR + EXT) as described in the
Methods section. Data are given mean SEM. N = 6. *P 0.04.
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Fig. 4. Longitudinal measurements of adipose tissue LPL activity and
mRNA (normalized against corresponding GAPDH mRNA) in the normal
control (solid lines) and chronic renal failure (dotted lines) groups. LPL
activity was measured as heparin-releasable (HR) and detergent-extract-
able (EXT) fractions and total activity (HR + EXT) as described in the
Methods section. Data are given as mean SCM. N = 6. p 0.05.
tion carried out in patients with end-stage renal disease [16].
However, EPO had no discernible effect on either LPL mRNA or
enzymatic activity of the tested tissues (Figs. 7 and 8). These
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This was accompanied by a modest cardiomegaly which was most
likely due to severe uncontrolled hypertension caused by EPO
therapy (Table 1). In addition,EPO therapy resulted in a mild
reduction of the CRF-associated hypertriglyceridemia and hyper-
cholesterolemia consistent with the results of an earlier investiga-
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Fig. 5. Relationship of heart, skeletal muscle and fat tissue total LPL activity
with serum triglyceride concentration obtained at week 6 in the normal control
(NL; •) and chronic renal fttilure (CRF; U) rats.
observations suggest that the effect of EPO on plasma triglycer-
ides and total cholesterol in the CRF animals does not involve
modification of LPL expression in the tested tissues.
Discussion
Chronic renal failure is commonly associated with hypertriglyc-
eridemia and elevated plasma VLDL level [1, 3]. These abnor-
malities are accompanied by triglyceride-enrichment of VLDL,
LDL, IDL and HDL particles [3, 6, 22] and impaired clearance of
0• I I
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Total LPL activity, nEq/min/g tissue
Fig. 6. Relationship of heart, skeletal muscle and fat tissue LPL ,nRNA
levels with the corresponding total LPL activities obtained in the normal
control (NL; •) and chronic renal ftuilure (CRF; U) animals.
VLDL, chylomicrons and their remnants as well as LDL and HDL
in humans and experimental animals with CRF [22—26]. In
addition, clearance of intravenously administered intralipids is
markedly prolonged in CRF patients [27].
LPL is a member of the large lipase gene family that includes
hepatic and pancreatic lipases. It is expressed in a variety of
tissues, particularly skeletal muscle, heart and adipose tissue. In
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Fig. 7. A representative autoradiograph of the Northern blot of heart, soleus
muscle and adipose tissue LPL and the corresponding GZ4PDH obtained at
week 6 in the nonnal control animals (NL, lane A) and those with chronic
renal failure treated with placebo (CRF, lane B) and EPO (cRE/EPO, lane
C).
the presence of Apo C-Il, LPL catalyzes the hydrolysis of triglyc-
erides contained in the triglyceride-rich lipoproteins, that is,
VLDL and chylomicrons. This results in the release of free fatty
acids which serve as a source of energy in heart and skeletal
muscle. Alternatively, free fatty acids generated are re-esterified
and stored as triglycerides in the adipose tissue [28]. Therefore,
LPL plays a major role in regulation of plasma lipoprotein and
energy metabolism. Primary and acquired forms of LPL deficiency
are associated with marked elevation of plasma triglyceride and
VLDL concentrations and impaired chylomicron clearance.
These features are frequently present in clinical and experimental
CRF, suggesting the possible role of LPL deficiency in the genesis
of CRF-induced hyperlipidemia. In fact, several studies have
demonstrated low post-heparin lipolytic activity and reduced
adipose tissue LPL activity in humans and experimental animals
with CRF [3, 8, 10, 15, 22, 29—31]. However, the effect of CRF on
gene expression of LPL has not been previously investigated.
The animals employed in the present study exhibited a steady
decline in LPL activities of the heart, skeletal muscle and adipose
tissue beginning one week after the induction of CRF. This was
accompanied by a parallel decline in LPL mRNA that was
particularly pronounced in the heart and skeletal muscle. In
contrast to the CRF group, the LPL activity and mRNA remained
unaltered during the study period in the sham-operated control
group. This observation suggests that the down-regulation of LPL
expression must be due to CRF. The gradual decline in LPL
expression in the CRF animals was accompanied by a steady rise
in plasma triglyceride concentration, In fact, plasma triglyceride
concentration showed a strong inverse correlation with the LPL
activity. These observations suggest the causal role of acquired
LPL deficiency in the genesis of the associated hypertriglyceride-
mia in the CRF animals. Down-regulation of LPL gene expression
shown here confirms the earlier assertion by Joven et a!, who
showed parallel reductions in plasma LPL activity and antigen in
a group of dialysis-dependent patients [15].
The reduction in LPL expression in the heart and skeletal
muscle, which depends on free fatty acids as a main source of
energy, may have additional implications beyond accumulation of
atherogenic triglyceride-rich lipoproteins in the circulation. In
fact, this phenomenon may be of significance to energy metabo-
lism in uremia and could, in part, contribute to weakness and
diminished exercise capacity, wasting syndrome and skeletal and
cardiac myopathies variably seen in uremia.
The reduction in adipose tissue LPL activity shown here in the
rat and by other investigators in humans [8] with CRF provides an
Fig. 8. Comparison of heart, skeletal muscle and fat tissue LPL activity and
LPL/GAPDH mRNA obtained at week 6 in the normal control rats (NL,
N = 6; E) and those with chronic renal failure treated with placebo (CRF,
N 6; tII) and EPO (CRE/EPO, N = 6; ).
explanation for the previously demonstrated reduction of triglyc-
eride content of adipose tissue in experimental CRF [32]. Hence,
acquired LPL deficiency may potentially interfere with the adi-
pose tissue storage of energy as triglyceride. It should be noted
, pØSee S..
•0SSS vit
1934 Vaziri and Liang: LPL deficiency in chronic renal failure
that the severity of LPL deficiency in adipose tissues of hemodi-
alysis patients reported in the above study was much greater than
that found in the CRF rats studied here. The reason for the
observed difference in severity of adipose tissue LPL deficiency is
unclear. However, it may be related to greater severity of renal
failure in dialysis-dependent patients and chronic intermittent
heparinization for hemodialysis which can potentially deplete
tissue-bound LPL. In addition, the presence of accompanying
systemic diseases in dialysis patients and their absence in the rat
model as well as species differences may contribute to this
phenomenon.
It is of interest that our CRF animals exhibited concomitant
declines in both muscle and adipose tissue LPL activity. This
phenomenon contrasts the ordinary circumstances where LPL
expression is inversely regulated in the two tissues playing oppo-
site roles in fatty acid metabolism (that is, fatty acid consumption
by myocyte vs. storage by adipocyte). Therefore, the effect of CRF
on LPL expression appears to be diffuse and largely nonspecific. It
is of note that the magnitude of the decline in LPL mRNA in the
adipose tissue was not as profound as that seen with skeletal and
cardiac muscles despite comparable reductions in LPL activity.
The reason for the difference in the relative values obtained in the
two tissue types is uncertain. However, it may be due to differ-
ences in the rates of gene transcription and mRNA stability or
translational and post-translational modifications in the two tis-
sues. Further studies are needed to address this issue and its
possible pathophysiological implications in CRF.
The observed down-regulation of LPL expression in CRF is
compounded by the reported elevation of Apo C-Ill (a potent
LPL inhibitor) coupled with relative reduction of Apo C-Il (a
known LPL activator) in CRF [33]. In addition, the effect of LPL
deficiency is further aggravated by the abundance of another
potent inhibitor in the uremic plasma recently identified by
Cheung et a! as pre-f3-HDL (free Apo A-I) [14]. This protein was
shown to be an equally potent LPL inhibitor as Apo C-Ill.
However, given its markedly higher concentration in the plasma,
the total inhibitory action of pre-/3-HDL is considerably greater
than that of APO C-Ill [14]. Hence, the impairment of LPL
activity in vivo is greater than that anticipated from the in vitro
experiments in which normal amounts of Apo C-TI, APO C-Ill
and pre--HDL are supplied in the test system.
LPL is synthesized as an inactive proenzyme in the endoplasmic
reticulum. The proenzyme undergoes activation by sequential
glycosylation and removal of a 24 amino acid peptide in the Golgi
apparatus. In addition, a significant portion of the newly synthe-
sized LPL is degraded in the lysosomes prior to secretion [28].
Within the cell the active and inactive forms of the enzyme are
stored in secretory vesicles which are translocated to the cell
surface via a cAMP-mediated process. The enzyme is then
released by an active process which can be up-regulated by
heparin. After secretion, LPL becomes anchored to the capillary
endothelial surface by binding to a specific heparan sulfate
proteoglycan receptor. Therefore, tissue LPL is divided into the
endothelial surface-bound compartment that can be competitively
dislodged from its binding sites by standard heparin (hence
designated as HR fraction) and that contained in the intracellular
vesicles (EXT fraction). Normally, the HR/EXT is greater in
adipose tissue as compared to the heart and skeletal muscle [28].
This pattern of distribution was observed in both CRF and normal
animals employed in the present study. The effect of uremia on
distributions of LPL within the two tissue compartments had not
been investigated previously and was examined here. We found
proportional reductions in the extracellular (HR) and intracellu-
lar (EXT) fractions of LPL in all tissues obtained from the CRF
animals. Hence, CRF-induced LPL deficiency affects the intracel-
lular and extracellular pools of LPL in a similar manner.
Regular administration of EPO has been shown to ameliorate
hyperlipidemia in patients with end-stage renal disease [16].
Consistent with the latter observations, EPO therapy resulted in
mild but significant reductions of plasma triglyceride and choles-
terol concentrations in the CRF animals employed here. How-
ever, EPO therapy did not lead to a discernible improvement of
CRF-associated down-regulation of LPL expression. This obser-
vation suggests that the effect of EPO therapy on plasma lipids is
not mediated by a detectable modification of LPL production.
This conclusion is, in part, supported by the reported findings of
depressed plasma LPL activity and antigen concentration in
EPO-treated patients on chronic hemodialysis therapy [151.
In conclusion, animals with CRF exhibited a marked and
progressive reduction in heart, skeletal muscle and adipose tissue
LPL expression accompanied by a marked rise in plasma triglyc-
eride level. Plasma triglycerides were inversely related to the LPL
activity in the study animals, suggesting the causal role of LPL
deficiency in the pathogenesis of CRF-induced hypertriglyceride-
mia.
Reprint requests to N.D. Vaziri, M.D., Division of Nephrology, UCI
Medical Center, 101 The Ci Drive, Orange, California, USA 92668.
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